Relevant myeloma and AL amyloidosis sessions at ASCO20 Virtual Scientific Program

  From 29 to 31 May, the American Society of Clinical Oncology (ASCO) will hold its annual scientific meeting. This is the largest, and one of the most important, oncology meetings in the calendar year. For the first time, ASCO20 will be held virtually adapting its programme and sessions to the COVID-19 situation. The programme will still feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and speciality tracks. All presentations will…

FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients

  Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.

MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?

  Myeloma Patients Europe (MPE) will hold a webinar on the impact of myeloma and AL amyloidosis in carers on Wednesday 20 May 2020 from 18:00 – 19:00 CET. The webinar will be given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK), who will give a 40-minute presentation followed by a 20-minute Q&A session.